Eli Lilly (LLY) Net Income (2009 - 2026)
Eli Lilly posted quarterly Net Income of $7.4 billion for Q1 2026, up 168.07% year-on-year from $2.8 billion in Q1 2025, and up 11.42% on a QoQ basis from $6.6 billion in Q4 2025.
Eli Lilly (LLY) has 17 years of Net Income data on file, last reported at $7.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Net Income rose 168.07% year-over-year to $7.4 billion; the trailing twelve-month figure through Mar 2026 stood at $25.3 billion (up 127.59% YoY), and the FY2025 full-year result was $20.6 billion, up 94.9% from the prior year.
- Net Income for Q1 2026 stood at $7.4 billion, up from $6.6 billion in the prior quarter.
- Across five years, Net Income topped out at $7.4 billion in Q1 2026 and bottomed at -$57.4 million in Q3 2023.
- The 5-year median for Net Income is $2.2 billion (2023), against an average of $2.9 billion.
- The widest annual swing landed in 2023, when Net Income tumbled 103.95%; it then surged 1790.42% in 2024.
- A 5-year view of Net Income shows it stood at $1.9 billion in 2022, then grew by 12.98% to $2.2 billion in 2023, then soared by 101.43% to $4.4 billion in 2024, then surged by 50.52% to $6.6 billion in 2025, then rose by 11.42% to $7.4 billion in 2026.
- The last three Net Income figures came in at $7.4 billion (Q1 2026), $6.6 billion (Q4 2025), and $5.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.40 Bn |
| Dec 31, 2025 | 6.64 Bn |
| Sep 30, 2025 | 5.58 Bn |
| Jun 30, 2025 | 5.66 Bn |
| Mar 31, 2025 | 2.76 Bn |
| Dec 31, 2024 | 4.41 Bn |
| Sep 30, 2024 | 970.30 Mn |
| Jun 30, 2024 | 2.97 Bn |
| Mar 31, 2024 | 2.24 Bn |
| Dec 31, 2023 | 2.19 Bn |
| Sep 30, 2023 | -57.40 Mn |
| Jun 30, 2023 | 1.76 Bn |
| Mar 31, 2023 | 1.34 Bn |
| Dec 31, 2022 | 1.94 Bn |
| Sep 30, 2022 | 1.45 Bn |
| Jun 30, 2022 | 952.50 Mn |
| Mar 31, 2022 | 1.90 Bn |
| Dec 31, 2021 | 1.73 Bn |
| Sep 30, 2021 | 1.11 Bn |
| Jun 30, 2021 | 1.39 Bn |
| Mar 31, 2021 | 1.36 Bn |
| Mar 31, 2019 | 3.68 Bn |
| Dec 31, 2018 | 3.70 Mn |
| Sep 30, 2018 | 55.90 Mn |
| Jun 30, 2018 | -28.30 Mn |
| Mar 31, 2018 | 50.20 Mn |
| Dec 31, 2017 | -1.55 Bn |
| Sep 30, 2017 | 555.60 Mn |
| Jun 30, 2017 | 1.01 Bn |
| Mar 31, 2017 | -110.80 Mn |
| Dec 31, 2016 | 771.80 Mn |
| Sep 30, 2016 | 778.00 Mn |
| Jun 30, 2016 | 747.70 Mn |
| Mar 31, 2016 | 440.10 Mn |
| Dec 31, 2015 | 478.40 Mn |
| Sep 30, 2015 | 799.70 Mn |
| Jun 30, 2015 | 600.80 Mn |
| Mar 31, 2015 | 529.50 Mn |
| Dec 31, 2014 | 428.50 Mn |
| Sep 30, 2014 | 500.60 Mn |
| Jun 30, 2014 | 733.50 Mn |
| Mar 31, 2014 | 727.90 Mn |
| Dec 31, 2013 | 727.50 Mn |
| Sep 30, 2013 | 1.20 Bn |
| Jun 30, 2013 | 1.21 Bn |
| Mar 31, 2013 | 1.55 Bn |
| Dec 31, 2012 | 827.20 Mn |
| Sep 30, 2012 | 1.33 Bn |
| Jun 30, 2012 | 923.60 Mn |
| Mar 31, 2012 | 1.01 Bn |
| Dec 31, 2011 | 858.20 Mn |
| Sep 30, 2011 | 1.24 Bn |
| Jun 30, 2011 | 1.20 Bn |
| Mar 31, 2011 | 1.06 Bn |
| Dec 31, 2010 | 1.17 Bn |
| Sep 30, 2010 | 1.30 Bn |
| Jun 30, 2010 | 1.35 Bn |
| Mar 31, 2010 | 1.25 Bn |
| Dec 31, 2009 | 915.40 Mn |
| Sep 30, 2009 | 941.80 Mn |
| Jun 30, 2009 | 1.16 Bn |
| Mar 31, 2009 | 1.31 Bn |